Journal
BLOOD
Volume 119, Issue 20, Pages 4587-4596Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-02-272682
Keywords
-
Categories
Funding
- National Institute of Neurological Disorders and Stroke [U01 NS042804]
- Burroughs Wellcome Translational Research Award [1006671]
- Action Medical Research
- Wellcome Trust [0353521/A/9294/Z, 056325/Z/98]
Ask authors/readers for more resources
Silent cerebral infarct (SCI) is the most common form of neurologic disease in children with sickle cell anemia (SCA). SCI is defined as abnormal magnetic resonance imaging (MRI) of the brain in the setting of a normal neurologic examination without a history or physical findings associated with an overt stroke. SCI occurs in 27% of this population before their sixth, and 37% by their 14th birthdays. In adults with SCA, the clinical history of SCI is poorly defined, although recent evidence suggests that they too may have ongoing risk of progressive injury. Risk factors for SCI include male sex, lower baseline hemoglobin concentration, higher baseline systolic blood pressure, and previous seizures. Specific morbidity associated with SCI includes a decrement in general intellectual abilities, poor academic achievement, progression to overt stroke, and progressive SCI. In addition, children with previous stroke continue to have both overt strokes and new SCI despite receiving regular blood transfusion therapy for secondary stroke prevention. Studies that only include overt stroke as a measure of CNS injury significantly underestimate the total cerebral injury burden in this population. In this review, we describe the epidemiology, natural history, morbidity, medical management, and potential therapeutic options for SCI in SCA. (Blood. 2012; 119(20):4587-4596)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available